Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2016 Dec;71(12):1110-1118.
doi: 10.1136/thoraxjnl-2016-208481. Epub 2016 Aug 11.

Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts

Affiliations
Multicenter Study

Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts

M J McDonnell et al. Thorax. 2016 Dec.

Abstract

Introduction: Bronchiectasis is a multidimensional disease associated with substantial morbidity and mortality. Two disease-specific clinical prediction tools have been developed, the Bronchiectasis Severity Index (BSI) and the FACED score, both of which stratify patients into severity risk categories to predict the probability of mortality.

Methods: We aimed to compare the predictive utility of BSI and FACED in assessing clinically relevant disease outcomes across seven European cohorts independent of their original validation studies.

Results: The combined cohorts totalled 1612. Pooled analysis showed that both scores had a good discriminatory predictive value for mortality (pooled area under the curve (AUC) 0.76, 95% CI 0.74 to 0.78 for both scores) with the BSI demonstrating a higher sensitivity (65% vs 28%) but lower specificity (70% vs 93%) compared with the FACED score. Calibration analysis suggested that the BSI performed consistently well across all cohorts, while FACED consistently overestimated mortality in 'severe' patients (pooled OR 0.33 (0.23 to 0.48), p<0.0001). The BSI accurately predicted hospitalisations (pooled AUC 0.82, 95% CI 0.78 to 0.84), exacerbations, quality of life (QoL) and respiratory symptoms across all risk categories. FACED had poor discrimination for hospital admissions (pooled AUC 0.65, 95% CI 0.63 to 0.67) with low sensitivity at 16% and did not consistently predict future risk of exacerbations, QoL or respiratory symptoms. No association was observed with FACED and 6 min walk distance (6MWD) or lung function decline.

Conclusion: The BSI accurately predicts mortality, hospital admissions, exacerbations, QoL, respiratory symptoms, 6MWD and lung function decline in bronchiectasis, providing a clinically relevant evaluation of disease severity.

Keywords: Bronchiectasis; Respiratory Infection.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Bar graphs showing quality of life, symptoms and lung function decline. For SGRQ and FEV1 decline, bars show mean with SEM. For Leicester Cough Questionnaire and 6 min walking distance, mean, SD and range are shown. BSI, Bronchiectasis Severity Index, SGRQ, St Georges Respiratory Questionnaire.

References

    1. Chalmers JD, Aliberti S, Blasi F. State of the Art: management of bronchiectasis in adults. Eur Respir J 2015;45:1446–62. 10.1183/09031936.00119114 - DOI - PubMed
    1. Quint JK, Millett ER, Joshi M, et al. . Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J 2016;47:186–93. 10.1183/13993003.01033-2015 - DOI - PMC - PubMed
    1. Ringshausen FC, de Roux A, Diel R, et al. . Bronchiectasis in Germany: a population-based estimation of disease prevalence. Eur Respir J 2015;46:1805–7. 10.1183/13993003.00954-2015 - DOI - PubMed
    1. Haworth CS, Foweraker JE, Wilkinson P, et al. . Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014;189:975–82. 10.1164/rccm.201312-2208OC - DOI - PMC - PubMed
    1. Wilson R, Welte T, Polverino E, et al. . Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013;41:1107–15. 10.1183/09031936.00071312 - DOI - PMC - PubMed

Publication types